<DOC>
	<DOCNO>NCT02114931</DOCNO>
	<brief_summary>The purpose open-label study evaluate long-term safety efficacy ABP 501 .</brief_summary>
	<brief_title>Long-term Safety Efficacy ABP 501 Subjects With Moderate Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject randomize protocol 20120262 complete week 26 visit Subject experience serious adverse event ( SAE ) adverse event ( AE ) 20120262 study could cause extension treatment detrimental Subject complete study 20120262 dose within 4 week week 26 visit study 20120262 Current infection require use oral intravenous antibiotic Other Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>81 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>arthritis</keyword>
	<keyword>rheumatoid</keyword>
</DOC>